President and CEO, Ambys Medicines
Jeff Jonker is President and CEO of Ambys Medicines. He joined Ambys from NGM Bio, where he served as President, leading the advancement of the company’s robust pipeline, including therapeutics for liver and metabolic diseases. Prior to joining NGM Bio, Jeff was Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG), and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, Jeff was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high-tech industries.
Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.